Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

49,672 (281,800) 206,587 (133,273)

INCOME TAX EXPENSE (BENEFIT) (62,371) 24,963 (4,375) 102,613

NET INCOME (LOSS) $112,043 $(306,763) $210,962 $(235,886)

BASIC INCOME (LOSS) PER

COMMON SHARE $1.64 $(4.58) $3.11 $(3.55)

DILUTED INCOME (LOSS) PER

COMMON SHARE $1.42 $(4.58) $2.79 $(3.55)

WEIGHTED AVERAGE NUMBER OF

COMMON SHARES OUTSTANDING 68,118 66,931 67,855 66,398

WEIGHTED AVERAGE NUMBER OF

COMMON SHARES OUTSTANDING-

ASSUMING DILUTION 78,920 66,931 75,580 66,398

CEPHALON, INC. AND SUBSIDIARIES

Reconciliation of GAAP Net Income to Adjusted Net Income

(Unaudited)

Three Months Ended

September 30,

2008 2007

GAAP NET (LOSS) INCOME $112,043 $(306,763)

Cost of sales adjustments 54,569 (1) 22,255 (1)

Research and development adjustments 259 (2) 15,000 (2)

Selling, general and administrative

adjustments 27,169 (3) -

Settlement reserve 7,450 (4) 369,000 (4)

Gain on extinguishment of debt - (5,319) (5)

Interest expense adjustment 3,750 (6)

Restructuring charges 1,497 (7)

Income tax adjustment (113,832) (8) (21,693) (8)

(19,138) 379,243

ADJUSTED NET INCOME $92,905 $72,480

BASIC ADJUSTED INCOME PER COMMON

SHARE $1.36
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Dr. Greg Leyer of UAS Labs ... Natural Supplements Pre-Conference seminar on probiotics in San Diego, CA. ... continuing education conference for health care professionals. This year’s pre-conference ... of probiotics in health. Dr. Leyer spoke about the emerging ...
(Date:1/22/2015)... SAN DIEGO , Jan. 22, 2015   ... company, and Sequenom, Inc. (NASDAQ: SQNM ... a development agreement for next generation noninvasive prenatal ... Cypher,s genome interpretation technology, called Mantis™, to advance ...
(Date:12/24/2014)... Md. , Dec. 24, 2014  United Therapeutics Corporation ... Inc. (NYSE: MDT ) has submitted a ... Administration (FDA) for the use of Medtronic,s SynchroMed ® ... developed catheter) for use with United Therapeutics, Remodulin ® ...
(Date:12/24/2014)... December 23, 2014 GMO corn cases filed ... are in the process of being consolidated in a Kansas ... Re: Syngenta AG MIR 162 Corn Litigation, MDL No. 2591 ... , Management of the Syngenta GMO corn multidistrict litigation (MDL) ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... , , NEW YORK, Dec. 15 ... is available in its catalogue: , The ... 2015, Pipeline Analysis and Reimbursement , ... , The author has released its latest research "The ...
... , WILMINGTON, Del. and CHARLOTTESVILLE, Va., ... and the University of Virginia (UVa) in Charlottesville, today ... collaboration to enhance development of new treatments primarily for ... peripheral vascular disease (PAD). , (Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO ...
... 15 The Mosaic Company (NYSE: MOS ) plans to ... tables on Tuesday, January 5, 2010, after the close of trading ... on Mosaic,s website at mosaicco.com/investors. , The Company will ... 2010, to discuss the results. The call will begin at ...
Cached Biology Technology:Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 2Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 3Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 4Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 5Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 6Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 7Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 8Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 9Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 10Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 11Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 12Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 13Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 14Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 15Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 16Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 17Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 18AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 2AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 3Mosaic Announces Second Quarter Fiscal Year 2010 Earnings Release and Conference Call 2
(Date:1/22/2015)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a biometric authentication ... success of the Wocket™ smart wallet at CES 2015 in ... as one of the "11 Hot Products at CES" in a review ... So Far" by Newseveryday.com and "The top 10 gadgets from CES 2015" ...
(Date:1/22/2015)... 22, 2015 Research and Markets ( ... "Global Wearable Technologies Market and Applications, Opportunities, ... and Forecast 2014-2020" report to their offering. ... devices that can be worn on the user,s ...
(Date:12/22/2014)... (NASDAQ: NXTD and NXTDW) ("NXT-ID" or the ... commerce market, announces it has retained famous pickpocket, entertainer and ... CES debut of the Wocket™ biometric smart wallet.  ... booth January 6th and 7 th , 2015, demonstrating some ...
Breaking Biology News(10 mins):CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4
... Insect Technique (SIT), the release of sexually sterile male insects ... to the problem of malaria in Africa. A new supplement, ... reviews the history of the technique, and features details about ... The supplement, edited by Dr Mark Benedict, who along with ...
... Researchers from the universities of Bristol and St. Andrews in ... skin affects how healthy and therefore attractive they appear, and ... most desirable complexion. The work will be published in the ... Using specialist computer software, a total of 54 ...
... , , SANTA ANA, ... ( SCMM, Prime Standard: SMY), a leading provider of solutions ... results for its third quarter ended September 30, 2009. In ... Corporation, revenue more than doubled, reflecting the success of the ...
Cached Biology News:Are sterile mosquitoes the answer to malaria elimination? 2Skin color gives clues to health 2SCM Microsystems Reports Third Quarter 2009 Results 2SCM Microsystems Reports Third Quarter 2009 Results 3SCM Microsystems Reports Third Quarter 2009 Results 4SCM Microsystems Reports Third Quarter 2009 Results 5SCM Microsystems Reports Third Quarter 2009 Results 6SCM Microsystems Reports Third Quarter 2009 Results 7SCM Microsystems Reports Third Quarter 2009 Results 8SCM Microsystems Reports Third Quarter 2009 Results 9SCM Microsystems Reports Third Quarter 2009 Results 10SCM Microsystems Reports Third Quarter 2009 Results 11SCM Microsystems Reports Third Quarter 2009 Results 12